EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

How to Handle Polypharmacy in Heart Failure. A Clinical Consensus Statement of the Heart Failure Association of the ESC

Davide Stolfo, Massimo Iacoviello, Ovidiu Chioncel, Markus S Anker, Antoni Bayes-Genis, Frieder Braunschweig, Antonio Cannata, Seif El Hadidi, Gerasimos Filippatos, Pardeep Jhund, Alexandre Mebazaa, Brenda Moura und 16 weitere

European Journal of Heart Failure · 01.05.2025 · 27 (5) · 747-759

DOI: 10.1002/ejhf.3642 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Journal of Heart Failure, online erschienen am 17.03.2025. Verfasst von Davide Stolfo und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Science and Education, Södersjukhuset; Karolinska Institutet, Stockholm, Sweden. Hauptthemen laut MEDLINE: Heart Failure, Polypharmacy, Consensus, Societies, Medical. Die Arbeit wurde bisher 59-mal zitiert (Crossref) und nennt 96 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The multiplicity of coexisting comorbidities affecting patients with heart failure (HF), together with the availability of multiple treatments improving prognosis in HF with reduced ejection fraction, has led to an increase in the number of prescribed medications to each patient. Polypharmacy is defined as the regular use of multiple medications, and over the last years has become an emerging aspect of HF care, particularly in older and frailer patients who are more frequently on multiple treatments, and are therefore more likely exposed to tolerability issues, drug–drug interactions and practical difficulties in management. Polypharmacy negatively affects adherence to treatment, and is associated with a higher risk of adverse drug reactions, impaired quality of life, more hospitalizations and worse prognosis. It is important to adopt and implement strategies for the management of polypharmacy from other medical disciplines, including medication reconciliation, therapeutic revision and treatment prioritization. It is also essential to develop new HF-specific strategies, with the primary goal of avoiding the use of redundant treatments, minimizing adverse drug reactions and interactions, and finally improving adherence. This clinical consensus statement document from the Heart Failure Association of the European Society of Cardiology proposes a rationale, pragmatic and multidisciplinary approach to drug prescription in the current era of multimorbidity and ‘multi-medication’ in HF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailurePolypharmacyConsensusSocieties, MedicalHumansMedication AdherenceQuality of LifeDrug Interactions

Stichwörter der Autor:innen

AdherenceComorbiditiesHeart failurePolypharmacy

Autor:innen und Institutionen

  • Department of Clinical Science and Education, Södersjukhuset; Karolinska Institutet, Stockholm, Sweden.
  • Division of Cardiology, Cardiothoracic Department, Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy.
  • Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.
  • University of Medicine Carol Davila, Bucharest, Romania.
  • Emergency Institute for Cardiovascular Diseases 'Prof. C.C. Iliescu', Bucharest, Romania.
  • German Heart Center Charité CBF and German Centre for Cardiovascular Research DZHK, Berlin, Germany.

ORCID-Profile: Gianluigi Savarese

Zitieren

APA

Stolfo, D., Iacoviello, M., Chioncel, O., Anker, M. S., Bayes-Genis, A., Braunschweig, F., Cannata, A., El Hadidi, S., Filippatos, G., Jhund, P., Mebazaa, A., Moura, B., Piepoli, M., Ray, R., Ristic, A. D., Seferovic, P., Simpson, M., Skouri, H., Tocchetti, C. G., …, & Savarese, G. (2025). How to Handle Polypharmacy in Heart Failure. A Clinical Consensus Statement of the Heart Failure Association of the ESC. European Journal of Heart Failure, 27(5), 747-759. https://doi.org/10.1002/ejhf.3642

Vancouver

Stolfo D, Iacoviello M, Chioncel O, Anker MS, Bayes-Genis A, Braunschweig F, et al. How to Handle Polypharmacy in Heart Failure. A Clinical Consensus Statement of the Heart Failure Association of the ESC. European Journal of Heart Failure. 2025;27(5):747-759. doi:10.1002/ejhf.3642

BibTeX
@article{Stolfo2025,
  author = {Stolfo, Davide and Iacoviello, Massimo and Chioncel, Ovidiu and Anker, Markus S and Bayes-Genis, Antoni and Braunschweig, Frieder and Cannata, Antonio and El Hadidi, Seif and Filippatos, Gerasimos and Jhund, Pardeep and Mebazaa, Alexandre and Moura, Brenda and Piepoli, Massimo and Ray, Robin and Ristic, Arsen D and Seferovic, Petar and Simpson, Maggie and Skouri, Hadi and Tocchetti, Carlo Gabriele and Van Linthout, Sophie and Vitale, Cristiana and Volterrani, Maurizio and Keramida, Kalliopi and Wassmann, Sven and Lewis, Basil S and Metra, Marco and Rosano, Giuseppe M C and Savarese, Gianluigi},
  title = {How to Handle Polypharmacy in Heart Failure. A Clinical Consensus Statement of the Heart Failure Association of the ESC},
  journal = {European Journal of Heart Failure},
  year = {2025},
  volume = {27},
  number = {5},
  pages = {747--759},
  doi = {10.1002/ejhf.3642}
}
Kostenlos starten →